Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/226244
Title: IMMUNOREGULATORY PROPERTIES OF CD137-CD137 LIGAND AXIS IN TUMOURS AND CHRONIC INFLAMMATORY CONDITIONS
Authors: LUU NGUYEN KHANG
ORCID iD:   orcid.org/0000-0003-2591-6552
Keywords: immunotherapy, CD137, immune checkpoint, trogocytosis, immunoregulatory
Issue Date: 17-Jan-2022
Citation: LUU NGUYEN KHANG (2022-01-17). IMMUNOREGULATORY PROPERTIES OF CD137-CD137 LIGAND AXIS IN TUMOURS AND CHRONIC INFLAMMATORY CONDITIONS. ScholarBank@NUS Repository.
Abstract: CD137 is a member of TNF receptor family, usually expressed on T and NK cells. Its natural ligand CD137L is a costimulatory molecule usually expressed on antigen presenting cells (APC). CD137 – CD137L interaction boosts immunity and activates anti-tumour or anti-viral responses. Curiously, CD137 is highly expressed on regulatory T cells and certain tumours. Thus, we explore how CD137 suppresses immunity and sustain chronic infection or tumour progression. Tumour and Treg can secrete soluble CD137, competing with membrane CD137 and impairing T cell polarization. CD137 can undergo trogocytosis to downregulate CD137L on APC, reducing their costimulatory ability. stimulate T cells. Stimulate CD137 on T cells also induces B7-H7, an exhaustion marker that impairs other T cells. CD137 signalling on tumour activates survival pathway p38-MAPK, IL-8 and LAMC2 which can promote tumour growth and metastasis. Finally, we devised PD1-CD137L fusion protein to upgrade the traditional checkpoint inhibitor therapy to counter these effects.
URI: https://scholarbank.nus.edu.sg/handle/10635/226244
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
NUS PhD thesis Immunoregulatory properties of CD137 final.pdf5.69 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

34
checked on Oct 6, 2022

Download(s)

4
checked on Oct 6, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.